4-(1H-苯并咪唑-2-基)-1-甲基-1H-吡唑-5-胺 | 88105-09-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 4-(1H-苯并咪唑-2-基)-1-甲基-1H-吡唑-5-胺
• 英文名称: 4-(benzo[d]thiazol-2-yl)-1-methyl-1H-pyrazol-5-amine
• 英文别名: 2-(3-amino-2-methylpyrazol-4-yl)benzimidazole；4-(1H-benzimidazol-2-yl)-1-methyl-1H-pyrazol-5-amine；4-(1H-benzimidazol-2-yl)-2-methylpyrazol-3-amine
• CAS: 88105-09-3
• 化学式: C₁₁H₁₁N₅
• mdl: MFCD08691316
• 分子量: 213.242
• InChiKey: UOKZBKZOSOVCSP-UHFFFAOYSA-N

物化性质

• 熔点：
  268-269 °C(Solv: ethanol (64-17-5); water (7732-18-5))
• 沸点：
  507.9±60.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  72.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(1H-苯并咪唑-2-基)-1-甲基-1H-吡唑-5-胺 、 原丙酸三乙酯 反应 3.0h， 以68%的产率得到10-Ethyl-1-methyl-1H-pyrazolo<3',4':4,5>pyrimido<1,6-a>benzimidazole
  参考文献：
  名称：

  Okamoto, Yoshihisa; Togo, Isao; Kurasawa, Yoshihisa, Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 1829 - 1831

  摘要：

  DOI：
• 作为产物：
  描述：

  4-amino-1H-1,5-benzodiazepine-3-carbonitrile hydrochloride 在 盐酸 、 sodium hydroxide 、 sodium carbonate 作用下， 反应 5.5h， 生成 4-(1H-苯并咪唑-2-基)-1-甲基-1H-吡唑-5-胺
  参考文献：
  名称：

  Okamoto, Yoshihisa; Ueda, Takeo; Takagi, Kaname, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 6, p. 2114 - 2119

  摘要：

  DOI：

文献信息

• HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3
  申请人：Harbeson L. Scott

  公开号：US20070270420A1

  公开（公告）日：2007-11-22

  The present invention relates to compounds of formula I useful as inhibitors of GSK-3 and Lck protein kinases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes, Alzheimer's disease, and transplant rejection.

  本发明涉及一种公式I的化合物，其可用作GSK-3和Lck蛋白激酶的抑制剂。本发明还提供了包含该发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗和预防各种疾病的方法，例如糖尿病、阿尔茨海默病和移植排斥反应。
• Heteroaryl compounds useful as inhibitors of GSK-3
  申请人：Vertex Pharmaceuticals, Inc.

  公开号：EP2322521A1

  公开（公告）日：2011-05-18

  The present invention relates to compounds of formula I useful as inhibitors of GSK-3 and Lck protein kinases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders, such as diabetes, Alzheimer's disease, and transplant rejection.

  本发明涉及可用作 GSK-3 和 Lck 蛋白激酶抑制剂的式 I 化合物。本发明还提供了包含本发明化合物的药学上可接受的组合物，以及利用这些组合物治疗和预防各种疾病（如糖尿病、阿尔茨海默病和移植排斥反应）的方法。
• Synthesis of novel biaryl 2-benzimidazoles and 2-benzothiazoles
  作者：Kanaka Pattabiraman、Rita El-Khouri、Kriti Modi、Lawrence R. McGee、David Chow

  DOI：10.1016/j.tetlet.2009.01.085

  日期：2009.4

  Herein, we describe the synthesis of the novel 4-(1H-benzo[d]imidazol-2-yl)isoxazol-5-amine (7) and 4-(1H-benzo[d]thiazol-2-yl)isoxazol-5-amine scaffolds (8). Initial attempts following literature procedures for the synthesis of similar compounds did not yield the desired product. Instead we obtained the ring-opened adduct 2-(1H-benzo[d]imidazol-2(3H)-ylidene)-2-cyanoacetamide (5). We were able to modify reaction conditions and successfully synthesize the desired product. We also describe a convenient one-pot microwave-assisted relay reaction for the synthesis of novel and reported 2-substituted benzimidazoles and benzothiazoles from inexpensive, commercially available reagents, 2-benzothiazole acetonitrile (2) and 2-benzimidazole acetonitrile (1). In all cases, good yields of products were obtained and reaction times were significantly reduced. (C) 2009 Elsevier Ltd. All rights reserved.
• OKAMOTO, YOSHIHISA;UEDA, TAKEO;TAKAGI, KANAME, CHEM. AND PHARM. BULL., 1983, 31, N 6, 2114-2119
  作者：OKAMOTO, YOSHIHISA、UEDA, TAKEO、TAKAGI, KANAME

  DOI：——

  日期：——
• Okamoto, Yoshihisa; Togo, Isao; Kurasawa, Yoshihisa, Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 1829 - 1831
  作者：Okamoto, Yoshihisa、Togo, Isao、Kurasawa, Yoshihisa、Takagi, Kaname

  DOI：——

  日期：——